Search Results

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

The Revi™ System is an implanted tibial electrical urinary continence device that wirelessly receives power from a non-implanted external wearable unit to provide electrical stimulation of the tibial nerve in proximity to the ankle. The device is intended for the treatment of urge urinary incontinence, alone or in combination with urinary urgency. The implantable device is implanted in the vicinity of the tibial neurovascular bundle. The treatment effect of the system is achieved by the implantable wireless neurostimulation component, which sends pulses to the tibial nerve when energized by the wearable unit transmitted power. The electrical pulses stimulate the nerve along the leg, reaching the sacral plexus and entering the spinal cord. This stimulation has the power to modulate nerve function, relieving symptoms.

The provided text is a 510(k) premarket notification letter from the FDA regarding the Revi™ System, a medical device for treating urgency incontinence. It outlines the FDA's determination of substantial equivalence to a predicate device and includes a 510(k) summary with device specifications and a discussion of performance testing.

However, the document does not contain the detailed information required to answer your specific questions concerning acceptance criteria, device performance, sample size, ground truth establishment, expert qualifications, or MRMC studies. The "Discussion of the Performance Testing" section is very brief and only mentions non-clinical benchtop testing for verification, not clinical studies with human participants that would generate performance metrics against specific acceptance criteria.

Therefore, I cannot populate the requested table or answer most of your questions based solely on the provided text. The document refers to "verification testing to ensure identical specification to predicate," which implies that the acceptance criteria for this 510(k) may have been tied to demonstrating that the new device (v4.3 software) performs comparably to the predicate device (v4.1.2.5 software) in bench tests.

Here's what I can extract, recognizing the limitations:

1. A table of acceptance criteria and the reported device performance:

2. Sample size used for the test set and the data provenance:

• The document only mentions "non-clinical benchtop testing." It does not specify a human "test set" and therefore no sample size, country of origin, or whether it was retrospective or prospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• Not applicable as no human test set or ground truth establishment by experts for performance evaluation is described in the provided text. The testing mentioned is for device specifications.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

• Not applicable as no human test set or adjudication process is described.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• This device is an implanted neurostimulation system, not an AI-assisted diagnostic tool. Therefore, an MRMC study and effects on human readers are not relevant and not mentioned.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• The performance described is essentially standalone in the sense that it's benchtop testing of the device's technical specifications. There's no "human-in-the-loop performance" described in the context of accepting the device's efficacy, only human factors/usability analysis to ensure no new critical tasks were introduced.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

• The "ground truth" for the verification testing appears to be the defined technical specifications of the device and its predicate, rather than clinical outcomes or expert consensus on a disease state.

8. The sample size for the training set:

• Not applicable. This document describes verification testing, not the development or training of an AI model.

9. How the ground truth for the training set was established:

• Not applicable.

In summary, the provided document focuses on demonstrating substantial equivalence through benchtop verification testing for a software update to an implanted medical device, not on clinical performance studies involving a test set, ground truth, or an AI algorithm.

Ask a specific question about this device

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

The Revi System is a tibial neuromodulation system that consists of the following four different components:

1. Implant: An implantable wireless neurostimulation component that is implanted in the vicinity of the tibial neurovascular bundle. The implant is battery-less and does not have an internal power source.
2. Rechargeable Wearable Unit: This unit is comprised of a wearable device and leg band. The wearable device contains an electrical circuit board, flexible antenna, and rechargeable battery with dedicated charger. The Rechargeable Wearable Unit, when used by the patient, is designed to be paired to a specific implant. Once paired, the Rechargeable Wearable Device transmits power and can only communicate (through magnetic coupling) with the specific implant to which it is paired.
3. Clinician Programmer (CP): This application is the system's interface used by the healthcare providers for treatment control, status evaluation, parameter programming and data acquisition. Access to the CP is password protected to allow access only to authorized users. The CP transfers data to and from the Rechargeable Wearable Unit via a wireless Bluetooth connection.
4. HealthGo Micro (Hub): The Hub communicates with the Rechargeable Wearable Unit using a Bluetooth connection and acquires and transmits data to the Cloud only during the charging sessions of the Rechargeable Unit. The Hub allows health care providers access to device data logs between visits without the need for in-person visits. The Hub is a Class I 510(k) exempt device (Product code OUG, 21 CFR 880.6310).

Acceptance Criteria and Device Performance for the Revi System

This document outlines the acceptance criteria for the Revi System and details the studies that demonstrate the device meets these criteria.

1. Table of Acceptance Criteria and Reported Device Performance

The Revi System's clinical performance was evaluated against primary and secondary effectiveness endpoints with pre-defined performance goals (PG). The device's safety was assessed by the incidence of adverse events.

Ask a specific question about this device